Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium

被引:375
作者
Biswas, B
Adhya, S
Washart, P
Paul, B
Trostel, AN
Powell, B
Carlton, R
Merril, CR
机构
[1] NIMH, NIH, Bethesda, MD 20892 USA
[2] Exponential Biotherapies Inc, Pt Washington, NY 11050 USA
关键词
D O I
10.1128/IAI.70.1.204-210.2002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Colonization of the gastrointestinal tract with vancomycin-resistant Enterococcus faecium (VRE) has become endemic in many hospitals and nursing homes in the United States. Such colonization predisposes the individual to VRE bacteremia and/or endocarditis, and immunocompromised patients are at particular risk for these conditions. The emergence of antibiotic-resistant bacterial strains requires the exploration of alternative antibacterial therapies, which led our group to study the ability of bacterial viruses (bacteriophages, or phages) to rescue mice with VRE bacteremia. The phage strain used in this study has lytic activity against a wide range of clinical isolates of VRE. One of these VRE strains was used to induce bacteremia in mice by intraperitoneal (i.p.) injection of 10(9) CFU. The resulting bacteremia was fatal within 48 h. A single i.p. injection of 3 x 10(8) PFU of the phage strain, administered 45 min after the bacterial challenge, was sufficient to rescue 100% of the animals. Even when treatment was delayed to the point where all animals were moribund, approximately 50% of them were rescued by a single injection of this phage preparation. The ability of this phage to rescue bacteremic mice was demonstrated to be due to the functional capabilities of the phage and not to a nonspecific immune effect. The rescue of bacteremic mice could be effected only by, phage strains able to grow in vitro on the bacterial host used to infect the animals, and when such strains are heat inactivated they lose their ability to rescue the infected mice.
引用
收藏
页码:204 / 210
页数:7
相关论文
共 19 条
[1]  
ACKERMANN HW, 1987, VIRUSES PROCARYOTES, P13
[2]   Bacteriophages show promise as antimicrobial agents [J].
Alisky, J ;
Iczkowski, K ;
Rapoport, A ;
Troitsky, N .
JOURNAL OF INFECTION, 1998, 36 (01) :5-15
[3]   TESTS FOR LINEAR TRENDS IN PROPORTIONS AND FREQUENCIES [J].
ARMITAGE, P .
BIOMETRICS, 1955, 11 (03) :375-386
[4]   Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential [J].
Barrow, PA ;
Soothill, JS .
TRENDS IN MICROBIOLOGY, 1997, 5 (07) :268-271
[5]  
Carlton Richard M., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P267
[6]  
Cimons M, 1999, ASM NEWS, V65, P800
[7]  
DRAPER NR, 1966, APPL REGRESSION ANAL, P47
[8]   FATE OF BACTERIOPHAGE-LAMBDA IN NON-IMMUNE GERMFREE MICE [J].
GEIER, MR ;
TRIGG, ME ;
MERRIL, CR .
NATURE, 1973, 246 (5430) :221-223
[9]  
Harlow E., 1999, Using Antibodies: A Laboratory Manual
[10]   PLASMID-MEDIATED RESISTANCE TO VANCOMYCIN AND TEICOPLANIN IN ENTEROCOCCUS-FAECIUM [J].
LECLERCQ, R ;
DERLOT, E ;
DUVAL, J ;
COURVALIN, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (03) :157-161